Hence, BH3 mimetics might represent an attractive approach of eliminating resistant subpopulations of cancer cells,
thereby targeting both tumor cell invasion and cancer relapse.
Because the toxin does
not target the tumor cells themselves but rather the host - derived blood vessel cells, the strategy could be efficacious for a wide range of tumor types, the NIH team notes.
Importantly, it's secretion from normal cells can be induced by activating p53 so that Par - 4 enters circulation, thereby
potentially targeting tumor cells at distant sites.
The second branch of the combination therapy, the low - dose metronomic chemotherapy, was similarly found to exert its therapeutic effect through a novel, hitherto unrecognized mechanism: The metronomic chemotherapy turned out to not
primarily target the tumor cells, but to act on the recruitment of yet another tumor - promoting cell population from the bone marrow.
Using this approach, immune cells are taken from a patient's bloodstream, reprogrammed to recognize and attack a specific protein found in cancer cells, then reintroduced into the patient's system, where they get to work
destroying targeted tumor cells.
In effect, Affigen uses cancer's «Achille's Heel»: the proteins which distinguish tumor cells from normal cells, that can
target tumor cells for destruction with extreme sensitivity and precision.
Tactiva Therapeutics utilizes a unique class of CD4 T cells that not only enhance the anti-tumor function of CD8 T cells, but also exhibit a capacity to
directly target the tumor cells.
«Few drugs have the capacity to cross the tumor blood - brain barrier and
specifically target tumor cells,» says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC — James.
The laboratory and animal study also shows how the agent, called SapC - DOPS,
targets tumor cells and blood vessels.
EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms:
targeting the tumor cell, the tumor environment, and the immune system.»
Delivery of these drugs, however, is not very efficient — only about 0.7 percent of chemotherapy nanodrugs reach
their target tumor cells.
T cells genetically engineered to make the chimeric antigen receptor can recognize and
target tumor cells.
DAP12 plays a critical role in activating the NK cells» cytotoxic pathways; therefore, lower levels of DAP12 in NK cells results in a reduced ability to
target tumor cells.
For instance, imaging could be used in new cancer treatments in which the patient's own immune system is employed to
target tumor cells.
Björn Frendéus, Ph.D., Chief Scientific Officer of BioInvent, and honorary Professor at Southampton University, said: «BI-1206 binds very specifically to the inhibitory FcyRIIB, a receptor that acts as a brake to dampen critical anti-cancer immune cell's function and to eliminate therapeutic antibody from
the targeted tumor cell surface.»
Once activated, the circuit expresses proteins designed to direct the immune system to
target the tumor cells, including surface T cell engagers, which direct T cells to kill the cells.
Durvalumab and tremelimumab are drugs in clinical development that block the PD - 1 / PD - L1 and CTLA - 4 pathways, respectively, and function to restimulate the immune system to
target tumor cells.
By targeting CTLA - 4, ipilimumab restimulates the immune system to
target tumor cells.
Despite its ability to
target tumor cells and promote an immune response, T - VEC has not been shown to improve overall survival or have an effect on visceral metastases.